EUVIMEDEUVIMED entdecken
Vergleichsstudie

Stage 0 hematogones essentially lack CD9 expression: comparative immunophenotypic analysis of hematogone subsets and myeloid blasts

Jessica Hughes, Joo Song iD, Huiyan Ma, Winston Lee, Karl Gaal, Parastou Tizro, Yan Liu, Elizabeth Quirk, Lori Soma

American Journal of Clinical Pathology · 04.11.2026 · 166 (5)

DOI: 10.1093/ajcp/aqag127 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 07.11.2026. Verfasst von Jessica Hughes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, City of Hope Medical Center, Duarte, CA, United States. Hauptthemen laut MEDLINE: Tetraspanin 29, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Myeloid Cells. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Measurable residual disease (MRD) assessment of B lymphoblastic leukemia (BLL) by flow cytometry (FC) can be confounded by normal populations, particularly stage 0 hematogones (HGs), following CD19-targeted therapy. Few studies have reported expression patterns or compared them with other populations. We assessed expression of CD9, CD34, CD45, CD58, CD66c/CD13/CD33, and CD81 on stage 0 HGs and compared the findings to stage 1 to 3 HGs and myeloid blasts (MBs).

Methods

Cases of BLL MRD FC were reviewed for residual disease, and negative cases with stage 0 HGs were further evaluated for stage 1 to 3 HGs and MBs. Dot plot patterns and median fluorescence intensity (MFI) were evaluated and compared across populations.

Results

Unlike stage 1 to 3 HGs, stage 0 HGs essentially lacked CD9 expression. CD9 MFI on stage 1 to 3 HGs demonstrated a broad range, typically with prominent bright components, although some cases showed significant CD9-negative subsets. Stage 0 HG CD34 was similar to stage 1 and slightly lower than MBs. CD45 expression was similar among stage 0 HGs, stage 1 HGs, and MBs. Although all HG stages appeared overall similar on dot plots, CD58 and CD66c/CD13/CD33 MFIs were higher, and CD81 MFI was lower in stage 0 HGs than in later stages. CD81 expression was higher in all HG stages compared with MBs.

Conclusions

Unlike stage 1 to 3 HGs, stage 0 HGs essentially lack CD9 expression. CD58, CD66c/CD13/CD33, and CD81 may show slight shifts in intensity compared with other stages. These findings should be considered when assessing BLL MRD by FC following CD19-directed therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tetraspanin 29Precursor B-Cell Lymphoblastic Leukemia-LymphomaMyeloid CellsHumansImmunophenotypingFlow CytometryNeoplasm, ResidualFemaleMaleAdult

Stichwörter der Autor:innen

BLLCD13CD33CD58CD66cCD81CD9MRDflow cytometryhematogonesstage 0

Substanzen

Tetraspanin 29CD9 protein, human

Autor:innen und Institutionen

  • Department of Pathology, City of Hope Medical Center, Duarte, CA, United States.
  • Department of Computation and Quantitative Medicine, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, United States.

ORCID-Profile: Joo Song

Zitieren

APA

Hughes, J., Song, J., Ma, H., Lee, W., Gaal, K., Tizro, P., Liu, Y., Quirk, E., & Soma, L. (2026). Stage 0 hematogones essentially lack CD9 expression: comparative immunophenotypic analysis of hematogone subsets and myeloid blasts. American Journal of Clinical Pathology, 166(5). https://doi.org/10.1093/ajcp/aqag127

Vancouver

Hughes J, Song J, Ma H, Lee W, Gaal K, Tizro P, et al. Stage 0 hematogones essentially lack CD9 expression: comparative immunophenotypic analysis of hematogone subsets and myeloid blasts. American Journal of Clinical Pathology. 2026;166(5). doi:10.1093/ajcp/aqag127

BibTeX
@article{Hughes2026,
  author = {Hughes, Jessica and Song, Joo and Ma, Huiyan and Lee, Winston and Gaal, Karl and Tizro, Parastou and Liu, Yan and Quirk, Elizabeth and Soma, Lori},
  title = {Stage 0 hematogones essentially lack CD9 expression: comparative immunophenotypic analysis of hematogone subsets and myeloid blasts},
  journal = {American Journal of Clinical Pathology},
  year = {2026},
  volume = {166},
  number = {5},
  doi = {10.1093/ajcp/aqag127}
}
Kostenlos starten →